Submission Details
| 510(k) Number | K140455 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | February 24, 2014 |
| Decision Date | May 22, 2014 |
| Days to Decision | 87 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
K140455 is an FDA 510(k) clearance for the CAPTIA MEASLES IGM, a Enzyme Linked Immunoabsorbent Assay, Rubeola Igm (Class I — General Controls, product code PCL), submitted by Trinity Biotech USA (Jamestown, US). The FDA issued a Cleared decision on May 22, 2014, 87 days after receiving the submission on February 24, 2014. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3520.
| 510(k) Number | K140455 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | February 24, 2014 |
| Decision Date | May 22, 2014 |
| Days to Decision | 87 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
| Product Code | PCL — Enzyme Linked Immunoabsorbent Assay, Rubeola Igm |
| Device Class | Class I — General Controls |
| CFR Regulation | 21 CFR 866.3520 |
| Definition | The Qualitative Detection Of Measles Specific Igm Antibodies In Serum Or Plasma. |